Benitec Biopharma Inc. (Nasdaq: BNTC) is delighted to announce the pricing of its underwritten public offering, comprising 15,544,041 shares of its common stock, along with accompanying warrants, pre-funded warrants and an option for the underwriter to purchase an additional 2,331,606 shares of common stock and/or common warrants. The combination offering price of $1.93 lends investors the chance to acquire one share of common stock, along with a common warrant to purchase one share of common stock, at the same time.
Moreover, pre-funded warrants, if any, will be immediately exercisable until exercised in full at an exercise price of only $0.0001 per share of common stock. The common warrant will be exercisable at an exercise price of $3.86 per share of common stock and will expire on the fifth anniversary of its initial exercise date. This public offering is expected to close on August 11, 2023, so be sure to seize this outstanding investment opportunity before it passes!
Benitec is expecting to generate approximately $30 million in gross proceeds from its public offering, before deducting underwriting discounts, commissions and other estimated expenses. Established players such as Adage Capital Partners LP, Janus Henderson Investors and Suvretta Capital have invested in the offering, and other new and existing investors are also taking part.
The Company is excited to use the proceeds from this financing to further the clinical development of BB-301 and progress development activities for other existing and new product candidates. Additionally, it will look for strategic growth opportunities to use these funds for general corporate purposes for a well-rounded, improved future.
JMP Securities, a Citizens Company, is proud to announce they have taken on the role of sole book-running manager for the offering. This opportunity provides a great chance for the firm to further its commitment to providing quality services to its clients. They strive to continue to be leaders in the industry and look forward to the success of this endeavor.
The Securities and Exchange Commission (“SEC”) has given the green light to a registration statement on Form S-1 regarding these securities, becoming effective on August 8, 2023. Once it has been completely finalized, a prospectus will be filed with the SEC that summarizes the details of this offering. Copies of the prospectus can be obtained from Citizens JMP Securities, LLC, located at 600 Montgomery Street, 10th Floor, San Francisco, CA 94111. Just send a request for the prospectus to their Prospectus Department.
Before investing, arm yourself with all the knowledge needed to make an informed decision. Go through the prospectus and other documents that the Company has filed or will file with the SEC to gain a deeper understanding of the business and its offering.
Invest in an opportunity you won’t want to miss! Now is the time to make an offer to buy the available securities. There will be no sale of securities in any jurisdiction without registration or qualification under the securities laws of the applicable state or jurisdiction. Take advantage of this limited time chance now!
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a leading clinical-stage biotechnology company based in Hayward, California, is blazing the way in genetic medicine. Their groundbreaking DNA-directed RNA interference program, “Silence and Replace”, harnesses RNA interference and gene therapy to provide simultaneous silencing of disease-causing genes and delivery of wildtype replacement genes with just one treatment. Benitec is paving the way to remedies for chronic and life-threatening conditions like Oculopharyngeal Muscular Dystrophy (OPMD).
Cautionary Note Concerning Forward-Looking Statements
Benitec is pleased to announce its proposed offering – but unfortunately, there is no guarantee that the offering will be completed as described, if at all. All investors should be aware of the potential risks associated with this offering, which can be found in Benitec’s SEC filings. Benitec is committed to keeping all stakeholders informed and up to date as the offering progresses, and will provide necessary updates as they become available.